Selling, General, and Administrative Costs: Pharming Group N.V. vs Ionis Pharmaceuticals, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Pharming Group N.V. and Ionis Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Ionis Pharmaceuticals consistently outspent Pharming Group, with its SG&A expenses peaking in 2020 at approximately 354% higher than its 2014 levels. Meanwhile, Pharming Group saw a steady increase, culminating in a 2022 peak that was over 3,160% higher than its 2014 expenses. This trend highlights Ionis's aggressive investment in administrative and sales functions, while Pharming Group's more conservative approach reflects a different strategic focus. As the biotech industry continues to evolve, these financial strategies will play a pivotal role in shaping the future of these companies.